Neurogene Inc. (NGNE)
| Market Cap | 757.63M +165.7% |
| Revenue (ttm) | n/a |
| Net Income | -111.11M |
| EPS | -5.04 |
| Shares Out | 20.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 132,067 |
| Open | 38.50 |
| Previous Close | 38.41 |
| Day's Range | 37.39 - 39.81 |
| 52-Week Range | 15.93 - 43.66 |
| Beta | 1.95 |
| Analysts | Strong Buy |
| Price Target | 80.43 (+112.44%) |
| Earnings Date | Aug 11, 2026 |
About NGNE
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The comp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for NGNE stock is "Strong Buy." The 12-month stock price target is $80.43, which is an increase of 112.44% from the latest price.
News
Neurogene price target lowered to $65 from $70 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Neurogene (NGNE) to $65 from $70 and keeps a Buy rating on the shares. The firm cites the company’s recent dilution for…
Neurogene price target raised to $81 from $69 at Guggenheim
Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Neurogene (NGNE) to $81 from $69 and keeps a Buy rating on the shares. The longer term Phase 1/2 data…
Neurogene price target lowered to $166 from $180 at Canaccord
Canaccord lowered the firm’s price target on Neurogene (NGNE) to $166 from $180 and keeps a Buy rating on the shares. The firm said its 2Q26 report was relatively uneventful…
Neurogene Slides: Corporate presentation
Neurogene has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Neurogene reports Q2 EPS ($1.53), consensus ($1.38)
“The second quarter and recent months marked important progress across our NGN-401 program, highlighted by positive long-term Phase 1/2 data showing durable, multidomain developmental gains that have ...
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Earnings release: Q2 2026
Neurogene released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Neurogene Quarterly report: Q2 2026
Neurogene has published its Q2 2026 quarterly earnings report on August 11, 2026.
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene prices 3.5M shares at $30.00 in public offering
Neurogene (NGNE) announced the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offering price per share of $30.00 and, in lieu…
Neurogene Inc. Announces Pricing of $125 Million Public Offering
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene 75M Spot Secondary; re-offered at $30.00
Leerink, Stifel, Guggenheim, LifeSci Capital and William Blair are acting as joint book running managers for the offering.
Neurogene announces common stock offering, no amount given
Neurogene (NGNE) announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants…
Neurogene Inc. Announces Proposed Public Offering
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: Study result
NGN-401 gene therapy for Rett syndrome showed 100% of phase I/II participants gained developmental milestones, with rapid, durable, and multi-domain improvements sustained up to 30 months. The therapy was well tolerated, exceeded efficacy thresholds, and is on track for regulatory submission and commercialization.
Neurogene Press release: Study result
Neurogene issued a press release on June 29, 2026, disclosing material business information to investors.
Neurogene Slides: Study result
Neurogene has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Neurogene announces data from Phase 1/2 trial of NGN-401
Neurogene (NGNE) announced updated, positive data from its Phase 1/2 clinical trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. Across 10 participants, 47 total de...
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene completes dosing in Embolden trial of NGN-401
Neurogene (NGNE) announced the successful completion of dosing in the Embolden registrational trial of NGN-401. While the initial enrollment target was 20 participants, the statistical analysis plan p...
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: AGM 2026
The meeting confirmed a quorum, elected two directors, approved executive compensation, ratified auditors, and set annual advisory votes on compensation. No shareholder proposals or questions were submitted.
Neurogene initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Neurogene (NGNE) with a Buy rating and $70 price target implying 170% upside from current levels. The company’s lead asset, NGN-401, is a one-time…
Neurogene reports Q1 EPS ($1.39), consensus ($1.27)
Cash, cash equivalents and short-term investments as of March 31, 2026 were $243.2 million and are expected to fund planned operations through the first quarter of 2028. “The significant unmet…
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...